Biosecure Act: The impact & what’s ahead — a BioCentury podcast

The broader implications of anti-China CDMO legislation

After quickly winding through Washington for six months, raising alarms and causing confusion as it mutated, the Biosecure Act is now on pause. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the delay for the legislation, which seeks to drive Chinese contract development and manufacturing organizations (CDMOs) out of the U.S., means, what will happen next, and how it will impact life sciences companies.